Scientists track rare bone disease over time
NCT ID NCT04783428
Summary
This study aims to observe and collect long-term information from 23 patients with a rare bone-softening disease called tumor-induced osteomalacia (TIO). It will track the safety and effectiveness of a specific drug (burosumab) for those taking it, and monitor the underlying tumor's behavior in all patients, regardless of their treatment. The study does not provide treatment; it only observes patients under their doctor's care.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TUMOR-INDUCED OSTEOMALACIA (TIO) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
IDIM - Instituto de Diagnóstico e Investigaciones Metabólicas
Buenos Aires, Argentina
-
Indiana University
Bloomington, Indiana, 47405, United States
-
Johns Hopkins University
Baltimore, Maryland, 21218, United States
-
University of Virginia
Charlottesville, Virginia, 22908, United States
-
Vanderbilt University Medical Center
Nashville, Tennessee, 37235, United States
-
Yale University
New Haven, Connecticut, 06520, United States
Conditions
Explore the condition pages connected to this study.